Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

Am J Hematol · 2021 · PMC8457116 · PMID 34062004

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

7.62 months; HR 0.54, 95% CI 0.23–1.30; one‐sided p = 0.082) (Table S3 ) showed a trend in favor of XVd over Vd.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Patients treated with XVd had numerically lower rates of death in both the standard risk group (21.6%) and in the high‐risk group (38.6%) as compared to Vd treated patients (28.7% and 43.7% respectively), although these trends did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.